Meeting
2015 ASCO Annual Meeting
Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Authors
Arndt Vogel
Hannover Medical School, Hannover, Germany
Arndt Vogel , Stefan Kasper , Wilko Weichert , Michael Bitzer , Andreas Block , Hanno Riess , Henning Schulze-Bergkamen , Markus H. Moehler , Kirsten Elisabeth Merx , Volker Endris , Elisabeth Schnoy , Jens T. Siveke , Patrick Michl , Dirk Waldschmidt , Jan Kuhlmann , Michael Geissler , Christoph Kahl , Stefan Kubicka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01320254
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4082)
DOI
10.1200/jco.2015.33.15_suppl.4082
Abstract #
4082
Poster Bd #
192
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.
First Author: Marcus Smith Noel
Poster
2015 Gastrointestinal Cancers Symposium
A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.
First Author: Francesco Leone
Poster
2017 ASCO Annual Meeting
Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology.
First Author: Radoslav Chekerov
Poster
2016 Gastrointestinal Cancers Symposium
Phase II study of fixed dose-rate gamcitabine plus S-1 as second-line treatment in advanced biliary tract cancer.
First Author: Satoshi Kobayashi